ARTICLE

Global Access Program

Working hand in hand to enable sustainable access to world-class diagnostics for the people who need them, when they need them – no matter where they live.

Take Aim Stop Disease

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Universal access to quality healthcare and medical innovation remains a global challenge.

In resource-limited regions, the need for reliable and sustainable healthcare and its supporting infrastructure is crucial in the fight against disease and advancing human health.

Recognising that diagnostics is an integral component for functioning health systems, in 2014 Roche launched the Global Access Program to enable access to reliable testing solutions for patients in low- and low-middle income countries (LMICs). Our goal is to use innovative solutions and leverage world-class expertise to establish diagnostics as a frontline defence against diseases such as HIV/AIDs, Tuberculosis (TB), Hepatitis B and C (HBV and HCV), COVID-19 and Human Papillomavirus (HPV)/ Cervical cancer.

By working together with international agencies, non-governmental organizations and governments at the global, regional and local level, we take a holistic and collaborative approach to improve health system diagnostic capacity.

HUMAN IMMUNODEFICIENCY VIRUS (HIV)

Join the leading provider of HIV viral load testing as it expands access to diagnostic testing for countries hardest hit by HIV.

TUBERCULOSIS (TB)

Take aim at tuberculosis. The leading killer of HIV-positive people, Roche is committed to working towards the WHO road map to stop this challenging infection.

HUMAN PAPILLOMAVIRUS (HPV)

Roche supports the WHO global strategy to eliminate cervical cancer by 2030 through access to HPV DNA screening for countries with high disease burden.

HEPATITIS B AND C (HBV AND HCV)

Hepatitis B and C are among the most common viral infections in the world. At least 263 million worldwide in 2017 – are carriers of hepatitis B or C virus infections, which can remain asymptomatic for decades.

COVID-19 (SARS-CoV-2)

Roche is deeply committed to supporting the global response to put an end to the COVID-19 pandemic.

Our range of solutions includes disease awareness and education programs, healthcare worker training, lab efficiency consulting and digital solutions. Through our partnerships we can help create scalable and sustainable solutions for laboratories, healthcare professionals and patients.

Our aim is to support international agencies and countries with a long term goal of establishing sustainable national programs.

Innovation in HIV testing

Redefine the reach of reliable testing. Making quantitative HIV viral load testing more accessible to those in remote areas.¹

Redefining access through innovative solutions

There are many barriers to accessing reliable diagnostics, proper treatment and care. In resource-limited settings, affordability is often a challenge. Through the Global Access Program, Roche provides sustainable pricing to governments and funders in eligible countries, alongside working with partners to deliver comprehensive solutions along the patient pathway.

In addition we develop innovative solutions specifically for challenges in LMICs. These include devices that simplify sample collection and transportation for reliable testing in rural settings and digital tools that empower patients to remain adherent to treatment and engaged in care.

Digital solutions for patients It's about time

Empowering patients to remain adherent to treatment and engaged in their care through education, reminders, and other elements. Designed specifically to address the complications in result delivery in many countries with the highest disease burdens. At the same time it is supporting healthcare workers with addressing clinic workflow challenges.

Roche Diagnostics joins force with nonprofit (RED) organization

Together, as a community, we can emphasize the importance of diagnostic testing as a critical step to reach the goal of an AIDS-free generation by 2030. Meeting UNAIDS elimination goals¹ is impossible without testing.

Optimising resource efficiency

Roche instruments have the capacity to test across multiple disease areas, making our solutions more resource efficient. This benefits national testing programs by testing more people, across more disease areas, in the most timely and cost-effective way.

Through a more integrated testing approach and network optimisation of diagnostic labs, it is possible to leverage strengths of different testing technologies and provide innovative solutions to build strong sample referral networks and ensure result return to reduce loss to follow up. By bringing together resource efficiency and physical accessibility in this way, we are able to provide access to diagnostics than ever before.

Since its inception, the Global Access Program has expanded substantially to provide increased access to diagnostics at affordable pricing for resource-constrained countries. It is part of Roche’s commitment to improving sustainable access to quality healthcare solutions for the people who need them, when they need them – no matter where they live.